



## Prevalence of toxoplasmosis and its association with dementia in older adults in central Africa: A result from the EPIDEMCA programme

Nathalie Bouscaren, Sophie Pilleron, Pascal Mbelesso, Bébène Ndamba-Bandzouzi, Jean-François Dartigues, Jean-Pierre Clément, Pierre-Marie Preux, Marie-Laure Dardé, Maëlen Guerchet

### ► To cite this version:

Nathalie Bouscaren, Sophie Pilleron, Pascal Mbelesso, Bébène Ndamba-Bandzouzi, Jean-François Dartigues, et al.. Prevalence of toxoplasmosis and its association with dementia in older adults in central Africa: A result from the EPIDEMCA programme. Tropical Medicine & International Health, 2018, 10.1111/tmi.13151 . hal-01891172

**HAL Id: hal-01891172**

**<https://unilim.hal.science/hal-01891172>**

Submitted on 16 Feb 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



## King's Research Portal

DOI:

[10.1111/tmi.13151](https://doi.org/10.1111/tmi.13151)

*Document Version*

Peer reviewed version

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Bouscaren, N., Pilleron, S., Mbelesso, P., Ndamba-Bandzouzi, B., Dartigues, J-F., Clement, J-P., Preux, P-M., Darde, M-L., & Guérchet, M. M. (2018). Prevalence of toxoplasmosis and its association with dementia in older adults in Central Africa: a result from the EPIDEMCA programme. *Tropical Medicine and International Health*, 23(12), 1304-1313. <https://doi.org/10.1111/tmi.13151>

### **Citing this paper**

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### **General rights**

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### **Take down policy**

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



## King's Research Portal

DOI:

[10.1111/tmi.13151](https://doi.org/10.1111/tmi.13151)

*Document Version*

Early version, also known as pre-print

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Bouscaren, N., Pilleron, S., Mbelesso, P., Ndamba-Bandzouzi, B., Dartigues, J-F., Clement, J-P., ... Guerchet, M. M. (2018). Prevalence of toxoplasmosis and its association with dementia in older adults in Central Africa: a result from the EPIDEMCA programme. *Tropical Medicine and International Health*, 23(12), 1304-1313.  
<https://doi.org/10.1111/tmi.13151>

### **Citing this paper**

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### **General rights**

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### **Take down policy**

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

# Tropical Medicine & International Health

## PREVALENCE OF TOXOPLASMOSIS AND ITS ASSOCIATION WITH DEMENTIA IN OLDER ADULTS IN CENTRAL AFRICA: A RESULT FROM THE EPIDEMCA PROGRAMME

--Manuscript Draft--

<b>Manuscript Number:</b>	TMIH-D-18-00094R2
<b>Full Title:</b>	PREVALENCE OF TOXOPLASMOSIS AND ITS ASSOCIATION WITH DEMENTIA IN OLDER ADULTS IN CENTRAL AFRICA: A RESULT FROM THE EPIDEMCA PROGRAMME
<b>Article Type:</b>	Original Research Paper
<b>Keywords:</b>	Dementia, Alzheimer's Disease, Toxoplasmosis, seroprevalence, older adults, sub-Saharan Africa
<b>Corresponding Author:</b>	Maelenn Guerchet, PhD UMR Inserm 1094 NET Limoges, FRANCE
<b>Corresponding Author Secondary Information:</b>	
<b>Corresponding Author's Institution:</b>	UMR Inserm 1094 NET
<b>Corresponding Author's Secondary Institution:</b>	
<b>First Author:</b>	Nathalie Bouscaren, MSc
<b>First Author Secondary Information:</b>	
<b>Order of Authors:</b>	Nathalie Bouscaren, MSc
	Sophie Pilleron, PhD
	Pascal Mbelesso, MD
	Bebene Ndamba-Bandzouzi, MD
	Jean-Francois Dartigues, MD, PhD
	Jean-Pierre Clement, MD, PhD
	Pierre-Marie Preux, MD, PhD
	Marie-Laure Darde, MD, PhD
	Maelenn Guerchet, PhD
<b>Order of Authors Secondary Information:</b>	
<b>Abstract:</b>	<p><b>Objective:</b> This study aimed at estimating the seroprevalence of <i>Toxoplasma gondii</i> infection in older adults living in Central Africa and at investigating its association with dementia using data from the Epidemiology of Dementia in Central Africa programme, a population-based study.</p> <p><b>Methods:</b> A cross-sectional multicenter population-based study was carried out among participants aged <math>\geq 65</math> years living in rural and urban areas of the Central African Republic and the Republic of Congo. Blood samples were collected from each consenting participant. The detection of anti-<i>T.gondii</i> immunoglobulin G antibodies was done in France using a commercially available ELISA kit. Participants were interviewed using a standardized questionnaire including sociodemographic characteristics. DSM-IV criteria were required for a diagnosis of dementia. Multivariate binary logistic regression models were used to estimate the association between toxoplasmosis infection and dementia.</p> <p><b>Results:</b> Among 1,662 participants, the seroprevalence of toxoplasmosis was 63.0% (95% confidence interval (CI): 60.7-65.3) overall, 66.6% (95%CI: 63.4-69.8) in Central African Republic and 59.4% (95%CI: 56.1-62.7) in the Republic of Congo. In multivariate analyses, toxoplasmosis status was significantly associated with</p>

	<p>increasing age (<math>p=0.006</math>), Republic of Congo (<math>p=0.002</math>), urban area (<math>p=0.001</math>) and previous occupation (<math>p=0.002</math>). No associations between dementia and toxoplasmosis status or anti- <i>T. gondii</i> IgG titres were found.</p> <p>Conclusion: Being infected with <i>T. gondii</i> was not associated with dementia among older adults in Central Africa. Our findings are consistent with some previous studies and add to the knowledge on the relationship between <i>T. gondii</i> infection and neurological disorders.</p>
--	--

PREVALENCE OF TOXOPLASMOSIS AND ITS ASSOCIATION WITH DEMENTIA IN OLDER  
ADULTS IN CENTRAL AFRICA: A RESULT FROM THE EPIDEMCA PROGRAMME

Nathalie Bouscaren<sup>1,2</sup>, Sophie Pilleron<sup>1,2</sup>, Pascal Mbelesso<sup>3</sup>, Bébène Ndamba-Bandzouzi<sup>4</sup>, Jean-  
François Dartigues<sup>5</sup>, Jean-Pierre Clément<sup>1,2,6</sup>, Pierre-Marie Preux<sup>1,2,7</sup>, Marie-Laure Dardé<sup>1,2,8</sup>,  
Maëlen Guérchet<sup>1,2,9\*</sup>, on the behalf of The EPIDEMCA group<sup>^</sup>

<sup>1</sup>INSERM UMR1094, Tropical Neuroepidemiology, Limoges, France

<sup>2</sup> University Hospital of Limoges, Faculty of Medicine, Institute of Neuroepidemiology and Tropical  
Neurology, CNRS FR 3503 GEIST, Limoges, France

<sup>3</sup>Department of Neurology, Amitié Hospital, Bangui, Central African Republic

<sup>4</sup>Department of Neurology, University Hospital of Brazzaville, Brazzaville, Republic of Congo

<sup>5</sup>INSERM U897, ISPED, Victor Segalen Bordeaux II University, Bordeaux, France

<sup>6</sup> Hospital and University Federation of Adult and Geriatric Psychiatry, Limoges, France

<sup>7</sup> University Hospital of Limoges, Centre of Epidemiology, Biostatistic, and Research Methodology,  
CEBIMER, Limoges, France

<sup>8</sup>Department of Parasitology and Biological Resource Centre for *Toxoplasma*, CHU Limoges, France

<sup>9</sup> King's College London, Centre for Global Mental Health, Institute of Psychiatry,  
Psychology and Neuroscience, Health Service and Population Research Department, London,  
United-Kingdom, De Crespigny Park, London, SE5 8AF, United Kingdom.

\*Corresponding author

Dr Maëlen GUERCHET

UMR Inserm 1094 Tropical Neuroepidemiology

24 Faculty of Medicine, 2 rue du Docteur Marcland

25 87025 Limoges, France.

26 Tel: +335 55 43 58 20, Fax: +335 55 43 58 21

27 E-mail: maelenn.guerchet@unilim.fr

28

29 ^ Membership of the EPIDEMCA group is provided in the Acknowledgements.

30

31 Running title: Toxoplasmosis and dementia in Central

32

**ABSTRACT (241 words)**

**Objective:** We aimed at estimating the seroprevalence of *Toxoplasma gondii* infection in older adults living in Central Africa and investigating its association with dementia using data from the Epidemiology of Dementia in Central Africa (EPIDEMCA) programme.

**Methods:** A cross-sectional multicentre population-based study was carried out among participants aged 73 ( $\pm 7$ ) years on average, living in rural and urban areas of the Central African Republic and the Republic of Congo between November 2011 and December 2012. Blood samples were collected from each consenting participant. The detection of anti-*T.gondii* immunoglobulin G antibodies was performed in 2014 in France using a commercially available ELISA kit. Participants were interviewed using a standardized questionnaire including sociodemographic characteristics. DSM-IV criteria were required for a diagnosis of dementia. Multivariate binary logistic regression models were used to estimate the association between toxoplasmosis infection and dementia.

**Results:** Among 1,662 participants, the seroprevalence of toxoplasmosis was 63.0% (95% confidence interval (CI): 60.7-65.3) overall, 66.6% (95%CI: 63.4-69.8) in Central African Republic and 59.4% (95%CI: 56.1-62.7) in the Republic of Congo. In multivariate analyses, toxoplasmosis status was significantly associated with increasing age ( $p=0.006$ ), Republic of Congo ( $p=0.002$ ), urban area ( $p=0.001$ ) and previous occupation ( $p=0.002$ ). No associations between dementia and toxoplasmosis status or anti- *T.gondii* IgG titres were found.

**Conclusion:** *T.gondii* infection was not associated with dementia among older adults in Central Africa. Our findings are consistent with previous studies and add to the knowledge on the relationship between *T.gondii* infection and neurological disorders.

**Keywords:** Dementia, Alzheimer's Disease, *Toxoplasma gondii*, seroprevalence, older adults, sub-Saharan Africa



## INTRODUCTION (3,103 words)

Globally, 25-30% of individuals are infected with *Toxoplasma gondii* (*T.gondii*) (1;2) with disparities across regions, depending on geographical and socio-economic conditions (1;2). Previous studies estimated at around 40% the prevalence of *T.gondii* infection in general population in the Republic of Congo (ROC) and in the Central African Republic (CAR) (3;4;4). *T.gondii* infection seroprevalence is primarily studied in population at risk for developing acute toxoplasmosis such as women of childbearing age and immuno-compromised patients. Although the risk of being infected with *T.gondii* increases with age (5), its prevalence among older adults and the effect of age on anti-*T.gondii* antibody titre evolution remain largely unknown.

During a primary *T.gondii* infection, the invasive tachyzoite stages circulate in the blood, invade the various organs, cross the blood-brain barrier and establish themselves in the brain cells probably as soon as the end of the first week of infection. This acute toxoplasmosis phase lasts a few weeks. It is usually asymptomatic, but can also present as a benign disease with lymphadenopathies, fever and asthenia. Beyond this acute phase, the invasive tachyzoite stages are no longer present, and the chronic stage of infection is characterized by the presence of latent toxoplasmic cysts in the tissues, and more particularly the central nervous system. This chronic stage is assumed to persist throughout life without inducing any symptoms in immunocompetent patients (1).

Dementia is a neurodegenerative disease characterized by progressive decline in cognitive functions, progressive functional impairment, and behavioural and psychological symptoms (6). Alzheimer's disease, characterized by two core cerebral lesions ( $\beta$  amyloid plaques and neurofibrillary tangles), is the most common cause of dementia among older people. Lewy Body disease, frontotemporal lobar degeneration, and vascular disease, are other common causes of dementia, differing in pathophysiology (7). However, mixed pathologies are much more common than 'pure' forms of dementia (8). Dementia has a significant impact on those affected, their families and society, with considerable costs worldwide (9). Demographic ageing worldwide is expected to lead to a dramatic increase in the number of cases, and African countries are not spared by this phenomenon (10). The

prevalence of dementia in adults aged 65 years and older was recently estimated between 6.4% and 8.5% in CAR and between 5.7% and 6.7% in ROC (11;12).

Literature studying the association between latent *T.gondii* infection and neurological or psychiatric disorders is growing (13-17). Chronic infection compromised goal-directed behaviour (18), affected several aspects of memory (19;20), led to a decline in visual motor coordination, coding ability and short term memory (21), and to a more rapid decline in executive function and cognitive decline among older adults (21). Cognitive dysfunctions were attributed to cysts' location in the brain (22;23), to the immune response in chronically infected patients (24), or to a change in cerebral metabolism (23;25). A chronic infection accompanied by an increase in interferon  $\gamma$  (IFN- $\gamma$ ) production decreases the tryptophan pool affecting kynurenic acid and serotonin levels. Moreover, *T.gondii* infection increases the activity of the tyrosine hydrolase that in turn releases dopamine. The increase in kynurenic acid and dopamine levels along with the decrease in serotonin level were associated with cognitive dysfunctions in rodents (23;26;27) and in humans (28). *T.gondii* infection was however shown to decrease  $\beta$ -amyloid plaque deposition in the cortex and hippocampus suggesting positive effects of *T.gondii* infection on the pathogenesis and progression of Alzheimer's disease (AD) in mice (29-31). In humans, case-control studies dedicated to *T.gondii* infection and dementia reported contradictory results (32-35). Most studies focused on the Alzheimer's subtype (32;33;35). Two studies found no association between AD and toxoplasmosis infection in the USA (33) and in Iran (32) whilst the third one in Turkey suggested that toxoplasma infection may be involved in the pathogenetic mechanisms of AD (35). The only study investigating dementia (all subtypes combined), in Egypt, showed that toxoplasma positive participants had an increased likelihood of having dementia, regardless of their ApoE genotype (34). To our knowledge, no study has been conducted in sub-Saharan African countries yet, where both dementia and *T. gondii* epidemiology may present particular aspects.

We aimed first at estimating the seroprevalence of *T.gondii* infection among older adults in Central Africa; secondly, at investigating the association between *T.gondii* infection and dementia, within the

Epidemiology of Dementia in Central Africa (EPIDEMCA) programme, a large population-based study.

## **METHODS**

### *Participants*

Our study population consisted of participants included in the EPIDEMCA programme, a multicentre cross-sectional population-based study conducted in CAR and ROC between November 2011 and December 2012. The detailed methodology is described in an open access publication (36). In essence, participants aged 65 years and older who had lived in the study area for at least six months were included. The study areas included the capitals of CAR (Bangui) and ROC (Brazzaville), and two rural areas (Nola in CAR and Gamboma in ROC). The sample size was calculated *a priori* with the aim of estimating dementia prevalence, and was then rounded at 500 in each study site. In absence of detailed census, the participants' selection in urban areas was carried out using a proportional random sampling (to represent Bangui and Brazzaville's diverse populations) while a door-to-door approach was preferred due to logistic and financial constraints in rural areas. Response rates varied between 93 and 97% across sites, with the only exclusion criteria being refusal or the presence of severe disease with short-term high risk of death.

Approvals were obtained from the ethical committee supervised by the Ministry of Public Health in CAR, the Comité d'Éthique de la Recherche en Sciences de Santé in ROC, and an ethical review board from the Comité de Protection des Personnes du Sud-Ouest et d'Outre-Mer 4 in France. All participants and/or their families gave informed consent prior to inclusion in the study. Written consent was obtained when feasible. Consent was obtained by thumbprint for illiterate people.

### *Serological analysis*

Each consenting participant had 20 mL of blood collected into two polypropylene EDTA tubes by a dedicated nurse. Whole fresh blood samples were centrifuged and aliquoted within few hours to avoid degradation due to high temperatures and then frozen at -20°C or -80°C in the nearest laboratory. Plasma aliquots were stored at the Pasteur Institute of Bangui in CAR and the National Laboratory of

Public Health in Brazzaville in ROC before dry-ice shipping to the University of Limoges where plasma samples were kept stored at -80°C until analysed. In 2014, the detection of anti-*T.gondii* immunoglobulin G (IgG) was done using the VIDAS TOXO IgG II test (Biomérieux, France), according to the manufacturer's instructions. This test is validated for detection of anti-*T.gondii* IgG in plasma. Results were reported in International Units per millilitre (IU/mL). Samples with anti-*T.gondii* IgG <4 IU/mL were considered as seronegative. A sample was considered as positive when the titre was equal or greater than 8 IU/mL. Samples with titres  $\geq 300$  IU/mL were diluted in the negative control included with the VIDAS TOXO IgG II test until titres could be determined. Titres comprised between 4 IU/mL and 8 IU/mL were considered as equivocal and further analysed by VIDAS TOXO competition (Biomérieux, France), which better correlated with low titres of the usual reference test, namely dye-test. Samples with indexes below 1.6 were considered as seropositive according to the manufacturer's instructions. The *T.gondii* positive group included all participants that were positive either with VIDAS Toxo IgG II or with VIDAS Toxo Competition assay.

#### *Dementia assessment*

Dementia was assessed following a two-stage process. First, cognitive screening was performed using the Community Screening Interview for Dementia (CSI-D) (37) adapted, back-translated and pretested in the local languages (Sango in CAR, Lari, Lingala, and Kituba in ROC). Every participant obtaining a poor performance on the CSI-D cognitive tests (COGSCORE  $\leq 24.5$ ) was suspected of having cognitive impairment and referred for neurological assessment. During the second phase which was conducted at the hospital 3-14 weeks later, further psychometric tests were conducted, including the Free and Cued Selective Reminding Test (38), Zazzo's cancellation task (39) and Isaac's Set Test of verbal fluency (40). Neurologists performed clinical examination, recorded history of stroke and presence of depressive disorders, and assessed orientation skills and daily activities. Dementia was diagnosed according to the DSM-IV criteria (6). An experienced neurologist (JFD) reviewed all medical records and cognitive test performances in order to reach a consensus.

#### *Statistical analysis*

Sociodemographic data included age, sex, marital status (married, never married/widowed/divorced/separated), education (no education, at least primary school), occupation (farmer/breeder/fisher vs. other), country (CAR, ROC) and area (urban, rural). Age was ascertained from official documents, using historical events or from an informant if previous methods were unsuccessful. All variables were collected during the first phase in all participants.

Study population characteristics were described in terms of means with corresponding standard deviations for age, median with its inter-quartiles range (IQR) for antibody titres and cognitive scores, and percentages for all categorical variables. Prevalence of toxoplasmosis was presented with its 95% confidence interval (CI). Comparisons were carried out between countries using the Chi-square test and Kruskal-Wallis test when appropriate. The correlation between the anti-IgG titre and age was tested using the Spearman test.

Factors associated with *T.gondii* infection were examined using logistic regression models. All factors associated with *T.gondii* infection and dementia at  $p < 0.20$  in univariate analysis were included in multivariate logistic regression model. The variable selection was carried out using a backward stepwise approach in which variables considered to be a confounder (odds ratio's variation above 15%) were kept in the model. The association between toxoplasmosis and dementia was first analysed in unadjusted logistic regression model and then in a model adjusted for age, sex, country, area and education.

In a sensitivity analysis, we ran the fully-adjusted logistic regression model with quintiles of anti-IgG titres as dependent variable instead of toxoplasmosis status.

The level of significance was fixed at 0.05 for all analyses. Statistical analyses were carried-out using Stata version 10.1 for Windows (StataCorp, College Station, TX).

## RESULTS

### *Characteristics of the EPIDEMCA participants*

Among 2,002 participants included in the EPIDEMCA study, 340 participants were excluded because they did not have blood samples due to refusals (n=176), impossible blood withdrawal (n=35), poor

health conditions (n=34), absence on the day of blood collections (n=9), and non-exploitable samples (n=86). A total of 1,662 participants were therefore analysed (Figure 1).

General socio-demographic characteristics are shown in Table 1. Participants were 73.1 ( $\pm$ 6.6) years on average and ROC participants were older and less likely living as a couple than those from CAR.

#### *Seroprevalence of Toxoplasma infection*

Of the 1,662 individuals, 1,047 were found to be positive for anti-*T.gondii* IgG antibodies, *i.e.* a seroprevalence of 63.0% (95%CI: 60.7-65.3). The seroprevalence was lower in ROC than in CAR ( $p=0.002$ ) and as a whole, lower in rural areas than urban areas (57.3% [95%CI: 53.9-60.7] vs. 68.5% [95%CI:65.4-71.6];  $p<0.001$ ) (Figure 2). In both country, the seroprevalence was significantly associated with areas ( $p<0.001$ ) but the urban-rural gradient was inversed.

In bivariate analyses, *T.gondii* infection was significantly associated with increasing age in 5-year bands, country, rural areas, no education, and previous occupation. In multivariate analysis, *T.gondii* infection remained significantly associated with country, area and previous occupation (Table 2).

Median anti-*T.gondii* IgG titre was 32 (IQR 120) IU/mL (min-max: 0-15 000), 22 (105) IU/mL in ROC and 47 (128) IU/mL in CAR ( $p<0.001$ ). A total of 99 participants (6.0%) had anti-*T.gondii* IgG titre>300 IU/mL, 44 (5.3%) in CAR and 55 (6.0%) in ROC ( $p=0.28$ ), and 48 (2.9%) had a titre above 1000 IU/mL, 21 (2.5%) in CAR and 27 (3.2%) in ROC ( $p=0.40$ ). No correlation between the anti-IgG titre and age was found ( $r=0.044$ ;  $p=0.07$ ).

#### *Association between T.gondii infection and dementia*

A total of 379 participants were excluded because cognitive status could not be determined for 276 of them (including 174 lost of follow up or missing) and 102 participants were diagnosed with MCI, resulting in an analytical sample size of 1,386 participants (Figure 1). Among them, 100 (7.2%) had dementia. Table 3 presents the socio-economic and clinical characteristics of participants with and without dementia. The *T.gondii* infection seroprevalence did not differ significantly based on the cognitive status: 64.0% (95%CI: 54.6-73.4) in participants with dementia *versus* 63.4% (95%CI: 60.7-66.0) in those without dementia ( $p=0.94$ ). In the unadjusted and adjusted models, no association was

shown between *T.gondii* seroprevalence and dementia (respectively OR=1.0 (95%CI: 0.7-1.6) and adjusted OR=1.0 (95%CI: 0.6-1.6)).

In a sensitivity analysis, we replaced the *Toxoplasma* infection status by quintiles of anti-IgG titre (Figure 3). No association was observed in both unadjusted (p=0.13) or adjusted models (p=0.36).

## DISCUSSION

To our knowledge, this large population-based study is the first study to investigate the prevalence of *T.gondii* infection in older native African adults and the first study to examine its relationship with dementia in the Central African context. We found a high prevalence of *T.gondii* infection in older people regardless of areas (urban or rural) and countries. However we did not find any association between *T.gondii* and dementia.

In African tropical countries, such as CAR and ROC, a high prevalence of toxoplasmosis is usually observed due to the low sanitary conditions, with poor or inexistent water treatment (1;2). In these conditions, soil, food and water contaminated with oocysts increase the risk of *T.gondii* infection.

The higher seroprevalence observed in CAR may be partly explained by the lower socioeconomic status in CAR compared to ROC (41). *T.gondii* infection was described as associated with poverty in different countries due to poor hygienic and sanitary conditions (42-44).

In our study, the seroprevalence was significantly higher in urban areas than in rural areas as a whole, but differences were observed at the country level. In CAR, the seroprevalence was higher in rural area than in urban area while, in ROC, an inverse rural-urban gradient was observed. In ROC, a more westernised lifestyle of Brazzaville inhabitants could lead to a more frequent meat intake than in Gamboma where meat is more expensive. Seroprevalence was also lower in people who worked or are working in farms, fisheries or with livestock. People performing better paid occupations may thus have access to a diet richer in fruits, vegetables and meat that may be contaminated with parasite. Unfortunately, soil exposure was not collected and data about food consumption were limited.

Heterogeneity in populations (women of childbearing age vs. older people) and design (case-control vs. cross-sectional survey) limits the comparison of our findings with other studies.

Surprisingly, we found a relatively large number of older adults with high antibody titres. Although studies on the evolution of the *T.gondii* serology in older populations are scarce (45), it is generally accepted that antibody titre decreases with age and are maintained at a low level over lifetime after an initial primary infection (46). Lifetime persistence of anti-*T.gondii* IgG results from continuous immune system stimulation by long-lasting tissue cysts. The usual decrease in antibody titres in older adults is hypothesized to be linked to the development of immunosenescence (47). Several hypotheses may explain the relatively high proportion of elevated titres in older people in our study: i) a primary infection during the sample collection. The detection of IgM antibodies could have confirmed this hypothesis, but it was not tested here due to financial constraints; ii) a reinfection by a different *Toxoplasma* strain that would have resulted in an increase in IgG titres. Indeed, clinical observations have shown that an immune response against a chronic infection does not prevent reinfection of immunocompetent individuals with a strain different than the one responsible for the primary infection (48). This hypothesis cannot be ruled out in our study since different genotypes have been identified in Central Africa (49-51). The immunosenescence or a T-cell exhaustion during a chronic infection (52) could facilitate the process of re-infection. iii) a non-specific and chronic immune stimulation due to different infectious agents (malaria, and other parasitic and viral diseases); iv) a genetic background leading to a higher humoral immune response in African population. Indeed, a high proportion (40.8%) of high levels of anti-*T.gondii* IgG (>400 IU/mL) was also reported in CAR in younger people (53).

Previous studies that examined the association between *T.gondii* chronic infection and Alzheimer's disease (AD) or dementia reported conflicting results (32-35). Our findings are contradictory with the ones of the only study assessing *T.gondii* infection as a correlate of dementia, carried out in a much younger population in Egypt (34). Different methodologies, including participant recruitment and statistical analyses, may explain these discrepancies. Another explanation may be the influence of the *T.gondii* strain on chronic brain infection in immunocompetent patients. In *in-vitro* cell culture systems, different immune responses or neurotransmitter expression were observed in human nervous cell infected by diverse *T.gondii* strains (54-56). In humans, a serotyping study suggested that



serological pattern consistent with Type I strain in mothers was more susceptible to be associated with psychosis in offspring (57). More recently, in a murine model of AD, only mice infected with a type II strain of *T.gondii*, a major lineage that predominates in Europe and North America, were protected against deposition of amyloid beta, a marker of AD, despite both type II and type III strains establishing a chronic CNS infection and inflammatory response (29). Mice infected with an attenuated type I strain that does not persist in mouse brain were not protected against amyloid beta deposition. Transposing data from animal models to human populations is particularly delicate as not all dementia subtypes share the same pathophysiological process and knowledge of the strains circulating in different countries is still incomplete (51;58;59). We however can reasonably think that our participants were infected by African strains, which share some genetic similarities with type I strains. Our results suggest that strains circulating in sub-Saharan Africa have no association with dementia.

The main strengths of our study are the use of a large, multicentre population-based design, the high number of participants with blood sample and a rigorous methodological method for establishing dementia diagnosis. However, a few limitations must be acknowledged. We were not able to analyse dementia sub-types, notably Alzheimer's disease, due to low frequencies. Additionally, we lack data that might influence our results such as timing of initial infection, interactions with other infectious diseases, and host genetic factors, as well as wealth or income which are potential confounders. Due to the study design, we are not able to rule out that earlier deaths due to *T.gondii* seropositivity obscured the association with dementia.

This large multicentre population-based study showed a high prevalence of *T.gondii* infection in older adults in Central Africa, with disparities in two neighbouring but different countries and areas related to socioeconomic and sanitary conditions. We failed to show any association between *T.gondii* chronic infection and dementia but future investigations should consider the association with Alzheimer's disease and Mild Cognitive Impairment. Another perspective would be to evaluate associated infectious agents as done for other neurological conditions (60).

## **Acknowledgments**

The authors would like to thank:

- French National Research Agency (ANR) for funding this study through the ANR-09-MNPS-009-01 grant

- the EPIDEMCA group (Maëleonn Guerchet, Bébène Ndamba-Bandzouzi, Pascal Mbelesso, Sophie Pilleron, Iléana Désormais, Philippe Lacroix, Victor Aboyans, Jean-Claude Desport, Pierre Jésus, Achille E. Tchalla, Benoît Marin, Jean-Pierre Clément, Jean-Charles Lambert, Jean-François Dartigues and Pierre-Marie Preux)

- the participants in the EPIDEMCA study

- the interviewers and nurses involved in this project for their assistance

- town halls, mayors, and chiefs of districts for their collaboration

- the Universities of Bangui (Central African Republic)

- Marien Ngouabi in Brazzaville (Republic of Congo)

- the Health ministries of the Central African Republic and the Republic of Congo, for their moral support

- University of Limoges.

## **Declaration of interest**

We declare that we have no conflict of interest.

## Reference List

- (1) Robert-Gangneux F, Darde ML. Epidemiology of and diagnostic strategies for toxoplasmosis. *Clin Microbiol Rev* 2012 Apr;25(2):264-96.
- (2) Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of *Toxoplasma gondii* seroprevalence and implications for pregnancy and congenital toxoplasmosis. *Int J Parasitol* 2009 Oct;39(12):1385-94.
- (3) Dumas N, Cazaux M, Carme B, Seguela JP, Charlet JP. [Toxoplasmosis in the Congo Republic. Seroepidemiological study]. *Bull Soc Pathol Exot* 1990;83(3):349-59.
- (4) Candolfi E, Berg M, Kien T. [Prevalence of toxoplasmosis in Pointe-Noire in Congo. Study of the sampling of 310 subjects]. *Bull Soc Pathol Exot* 1993;86(5):358-62.
- (5) Wilking H, Thamm M, Stark K, Aebischer T, Seeber F. Prevalence, incidence estimations, and risk factors of *Toxoplasma gondii* infection in Germany: a representative, cross-sectional, serological study. *Sci Rep* 2016 Mar 3;6:22551.
- (6) American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 2018. Report No.: 4 ed. 2000.
- (7) Hickey E.M., Bourgeois M.C. Dementia: Person-Centered Assessment and Intervention. 2018.
- (8) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). *Lancet* 2001 Jan 20;357(9251):169-75.
- (9) World Alzheimer Report 2015. The global impact of Dementia. *Alzheimer's Disease International*; 2015.
- (10) Guerchet M. Dementia in sub-Saharan Africa: challenges and opportunities. *Alzheimer's Disease International* . 2017.
- (11) Guerchet M, M'belesso P, Mouanga AM, Bandzouzi B, Tabo A, Houinato DS, et al. Prevalence of dementia in elderly living in two cities of Central Africa: the EDAC survey. *Dement Geriatr Cogn Disord* 2010;30(3):261-8.
- (12) Guerchet M, Ndamba-Bandouzi B, Mbelesso P, Pilleron S, Clement JP, Dartigues JF, et al. Comparison of rural and urban dementia prevalences in two countries of Central Africa: The EPIDEMCA Study. *The journal of Alzheimer's Association* 9[4], 688. 7-1-2013. The.
- (13) Pearce BD, Kruszon-Moran D, Jones JL. The relationship between *Toxoplasma gondii* infection and mood disorders in the third National Health and Nutrition Survey. *Biol Psychiatry* 2012 Aug 15;72(4):290-5.
- (14) Ngoungou EB, Bhalla D, Nzoghe A, Darde ML, Preux PM. Toxoplasmosis and epilepsy--systematic review and meta analysis. *PLoS Negl Trop Dis* 2015 Feb;9(2):e0003525.
- (15) Fabiani S, Pinto B, Bruschi F. Toxoplasmosis and neuropsychiatric diseases: can serological studies establish a clear relationship? *Neurol Sci* 2013 Apr;34(4):417-25.

- 354 (16) Severance EG, Xiao J, Jones-Brando L, Sabunciyan S, Li Y, Pletnikov M, et al. *Toxoplasma*  
355 *gondii*-A Gastrointestinal Pathogen Associated with Human Brain Diseases. *Int Rev*  
356 *Neurobiol* 2016;131:143-63.
- 357 (17) Del GC, Galli L, Schiavi E, Dell'Osso L, Bruschi F. Is *Toxoplasma gondii* a Trigger of  
358 Bipolar Disorder? *Pathogens* 2017 Jan 10;6(1).
- 359 (18) Beste C, Getzmann S, Gajewski PD, Golka K, Falkenstein M. Latent *Toxoplasma gondii*  
360 infection leads to deficits in goal-directed behavior in healthy elderly. *Neurobiol Aging* 2014  
361 May;35(5):1037-44.
- 362 (19) Gajewski PD, Falkenstein M, Hengstler JG, Golka K. *Toxoplasma gondii* impairs memory in  
363 infected seniors. *Brain Behav Immun* 2014 Feb;36:193-9.
- 364 (20) Mendy A, Vieira ER, Albatineh AN, Gasana J. Immediate rather than delayed memory  
365 impairment in older adults with latent toxoplasmosis. *Brain Behav Immun* 2015 Mar;45:36-  
366 40.
- 367 (21) Nimgaonkar VL, Yolken RH, Wang T, Chang CC, McClain L, McDade E, et al. Temporal  
368 Cognitive Decline Associated With Exposure to Infectious Agents in a Population-based,  
369 Aging Cohort. *Alzheimer Dis Assoc Disord* 2016 Jul;30(3):216-22.
- 370 (22) Prandota J. Possible link between *Toxoplasma gondii* and the anosmia associated with  
371 neurodegenerative diseases. *Am J Alzheimers Dis Other Dement* 2014 May;29(3):205-14.
- 372 (23) McConkey GA, Martin HL, Bristow GC, Webster JP. *Toxoplasma gondii* infection and  
373 behaviour - location, location, location? *J Exp Biol* 2013 Jan 1;216(Pt 1):113-9.
- 374 (24) Hamdani N, Daban-Huard C, Lajnef M, Gadel R, Le CP, Delavest M, et al. Cognitive  
375 deterioration among bipolar disorder patients infected by *Toxoplasma gondii* is correlated to  
376 interleukin 6 levels. *J Affect Disord* 2015 Jul 1;179:161-6.
- 377 (25) Carruthers VB, Suzuki Y. Effects of *Toxoplasma gondii* infection on the brain. *Schizophr Bull*  
378 2007 May;33(3):745-51.
- 379 (26) Prandovszky E, Gaskell E, Martin H, Dubey JP, Webster JP, McConkey GA. The neurotropic  
380 parasite *Toxoplasma gondii* increases dopamine metabolism. *PLoS One* 2011;6(9):e23866.
- 381 (27) Carter CJ. Toxoplasmosis and Polygenic Disease Susceptibility Genes: Extensive *Toxoplasma*  
382 *gondii* Host/Pathogen Interactome Enrichment in Nine Psychiatric or Neurological Disorders.  
383 *J Pathog* 2013;2013:965046.
- 384 (28) Xiao J, Li Y, Prandovszky E, Karuppagounder SS, Talbot CC, Jr., Dawson VL, et al.  
385 MicroRNA-132 dysregulation in *Toxoplasma gondii* infection has implications for dopamine  
386 signaling pathway. *Neuroscience* 2014 May 30;268:128-38.
- 387 (29) Cabral CM, McGovern KE, MacDonald WR, Franco J, Koshy AA. Dissecting Amyloid Beta  
388 Deposition Using Distinct Strains of the Neurotropic Parasite *Toxoplasma gondii* as a Novel  
389 Tool. *ASN Neuro* 2017 Jul;9(4):1759091417724915.
- 390 (30) Mohle L, Israel N, Paarmann K, Krohn M, Pietkiewicz S, Muller A, et al. Chronic  
391 *Toxoplasma gondii* infection enhances beta-amyloid phagocytosis and clearance by recruited  
392 monocytes. *Acta Neuropathol Commun* 2016 Mar 16;4:25.

- 393 (31) Jung BK, Pyo KH, Shin KY, Hwang YS, Lim H, Lee SJ, et al. Toxoplasma gondii infection in  
394 the brain inhibits neuronal degeneration and learning and memory impairments in a murine  
395 model of Alzheimer's disease. PLoS One 2012;7(3):e33312.
- 396 (32) Mahami-Oskouei M, Hamidi F, Talebi M, Farhoudi M, Taheraghdam AA, Kazemi T, et al.  
397 Toxoplasmosis and Alzheimer: can Toxoplasma gondii really be introduced as a risk factor in  
398 etiology of Alzheimer? Parasitol Res 2016 Aug;115(8):3169-74.
- 399 (33) Perry CE, Gale SD, Erickson L, Wilson E, Nielsen B, Kauwe J, et al. Seroprevalence and  
400 Serointensity of Latent Toxoplasma gondii in a Sample of Elderly Adults With and Without  
401 Alzheimer Disease. Alzheimer Dis Assoc Disord 2016 Apr;30(2):123-6.
- 402 (34) Yahya RS, Awad SI, El-Baz HA, Saudy N, Abdelsalam OA, Al-Din MS. Impact of ApoE  
403 genotypes variations on Toxoplasma patients with dementia. J Clin Neurosci 2017  
404 May;39:184-8.
- 405 (35) Kusbeci OY, Miman O, Yaman M, Aktepe OC, Yazar S. Could Toxoplasma gondii have any  
406 role in Alzheimer disease? Alzheimer Dis Assoc Disord 2011 Jan;25(1):1-3.
- 407 (36) Guerchet M, Mbelesso P, Ndamba-Bandzouzi B, Pilleron S, Desormais I, Lacroix P, et al.  
408 Epidemiology of dementia in Central Africa (EPIDEMCA): protocol for a multicentre  
409 population-based study in rural and urban areas of the Central African Republic and the  
410 Republic of Congo. Springerplus 2014;3:338.
- 411 (37) Hall KS, Gao S, Emsley CL, Ogunniyi AO, Morgan O, Hendrie HC. Community screening  
412 interview for dementia (CSI 'D'); performance in five disparate study sites. Int J Geriatr  
413 Psychiatry 2000 Jun;15(6):521-31.
- 414 (38) Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory  
415 testing. Neurology 1988 Jun;38(6):900-3.
- 416 (39) Zazzo R. [Test des deux barrages. Actualités pédagogiques et psychologiques]. Neuchatel 7.  
417 1974.
- 418 (40) Isaacs B, Kennie AT. The Set test as an aid to the detection of dementia in old people. Br J  
419 Psychiatry 1973 Oct;123(575):467-70.
- 420 (41) World Bank Group. 2018.
- 421 (42) Bahia-Oliveira LM, Jones JL, Azevedo-Silva J, Alves CC, Orefice F, Addiss DG. Highly  
422 endemic, waterborne toxoplasmosis in north Rio de Janeiro state, Brazil. Emerg Infect Dis  
423 2003 Jan;9(1):55-62.
- 424 (43) Frenkel JK, Dubey JP. Toxoplasmosis and its prevention in cats and man. J Infect Dis 1972  
425 Dec;126(6):664-73.
- 426 (44) Hotez PJ. Neglected parasitic infections and poverty in the United States. PLoS Negl Trop Dis  
427 2014 Sep;8(9):e3012.
- 428 (45) Engroff P, Ely LS, Guiselli SR, Goularte FH, Gomes I, Viegas K, et al. [Seroepidemiology of  
429 Toxoplasma gondii in elderly individuals treated under the Family Health Strategy, Porto  
430 Alegre, Rio Grande do Sul, Brazil]. Cien Saude Colet 2014 Aug;19(8):3385-93.
- 431 (46) Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004 Jun 12;363(9425):1965-76.

- 432 (47) Weiskopf D, Weinberger B, Grubeck-Loebenstien B. The aging of the immune system.  
433 Transpl Int 2009 Nov;22(11):1041-50.
- 434 (48) Elbez-Rubinstein A, Ajzenberg D, Darde ML, Cohen R, Dumetre A, Yera H, et al. Congenital  
435 toxoplasmosis and reinfection during pregnancy: case report, strain characterization,  
436 experimental model of reinfection, and review. J Infect Dis 2009 Jan 15;199(2):280-5.
- 437 (49) Ajzenberg D, Yera H, Marty P, Paris L, Dalle F, Menotti J, et al. Genotype of 88 *Toxoplasma*  
438 *gondii* isolates associated with toxoplasmosis in immunocompromised patients and correlation  
439 with clinical findings. J Infect Dis 2009 Apr 15;199(8):1155-67.
- 440 (50) Mercier A, Devillard S, Ngoubangoye B, Bonnabau H, Banuls AL, Durand P, et al. Additional  
441 haplogroups of *Toxoplasma gondii* out of Africa: population structure and mouse-virulence of  
442 strains from Gabon. PLoS Negl Trop Dis 2010 Nov 2;4(11):e876.
- 443 (51) Galal L, Ajzenberg D, Hamidovic A, Durieux MF, Darde ML, Mercier A. *Toxoplasma* and  
444 Africa: One Parasite, Two Opposite Population Structures. Trends Parasitol 2018  
445 Feb;34(2):140-54.
- 446 (52) Gigley JP, Bhadra R, Moretto MM, Khan IA. T cell exhaustion in protozoan disease. Trends  
447 Parasitol 2012 Sep;28(9):377-84.
- 448 (53) Morvan JM, Mambely R, Selekon B, Coumanzi-Malo MF. [Toxoplasmosis at the Pasteur  
449 Institute of Bangui, Central African Republic (1996-1998): serological data]. Bull Soc Pathol  
450 Exot 1999 Jul;92(3):157-60.
- 451 (54) Mammari N, Vignoles P, Halabi MA, Darde ML, Courtioux B. In vitro infection of human  
452 nervous cells by two strains of *Toxoplasma gondii*: a kinetic analysis of immune mediators  
453 and parasite multiplication. PLoS One 2014;9(6):e98491.
- 454 (55) Xiao J, Jones-Brando L, Talbot CC, Jr., Yolken RH. Differential effects of three canonical  
455 *Toxoplasma* strains on gene expression in human neuroepithelial cells. Infect Immun 2011  
456 Mar;79(3):1363-73.
- 457 (56) Xiao J, Li Y, Jones-Brando L, Yolken RH. Abnormalities of neurotransmitter and  
458 neuropeptide systems in human neuroepithelioma cells infected by three *Toxoplasma* strains. J  
459 Neural Transm (Vienna ) 2013 Dec;120(12):1631-9.
- 460 (57) Xiao J, Buka SL, Cannon TD, Suzuki Y, Viscidi RP, Torrey EF, et al. Serological pattern  
461 consistent with infection with type I *Toxoplasma gondii* in mothers and risk of psychosis  
462 among adult offspring. Microbes Infect 2009 Nov;11(13):1011-8.
- 463 (58) Chaichan P, Mercier A, Galal L, Mahittikorn A, Ariei F, Morand S, et al. Geographical  
464 distribution of *Toxoplasma gondii* genotypes in Asia: A link with neighboring continents.  
465 Infect Genet Evol 2017 Sep;53:227-38.
- 466 (59) Shwab EK, Zhu XQ, Majumdar D, Pena HF, Gennari SM, Dubey JP, et al. Geographical  
467 patterns of *Toxoplasma gondii* genetic diversity revealed by multilocus PCR-RFLP  
468 genotyping. Parasitology 2014 Apr;141(4):453-61.
- 469 (60) Kamuyu G, Bottomley C, Mageto J, Lowe B, Wilkins PP, Noh JC, et al. Exposure to multiple  
470 parasites is associated with the prevalence of active convulsive epilepsy in sub-Saharan  
471 Africa. PLoS Negl Trop Dis 2014;8(5):e2908.

472 Table 1: Sociodemographic characteristics of participants based on country (n=1,662), EPIDEMCA,  
 473 2011-2012  
 474

	<b>Total</b>	<b>CAR</b>	<b>ROC</b>	<b><i>p</i></b>
<b>Sample, n</b>	1662	827	835	
<b>Age (years), n (%)</b>				<b>0.010</b>
65-69	608 (36.6)	329 (39.8)	279 (33.4)	
70-74	427 (25.7)	216 (26.1)	211 (25.3)	
75-79	327 (19.7)	153 (18.5)	174 (20.8)	
80 +	300 (18.1)	129 (15.6)	171 (20.5)	
<b>Sex, n (%)</b>				0.583
Males	644 (38.8)	315 (38.1)	329 (39.4)	
Females	1018 (61.3)	512 (61.9)	506 (60.6)	
<b>Area, n (%)</b>				0.085
Urban	847 (51.0)	439 (53.1)	408 (48.9)	
Rural	815 (49.0)	388 (46.9)	427 (51.1)	
<b>Education, n (%)</b>				0.812
No education	1148 (69.2)	569 (68.9)	579 (69.4)	
At least primary school	512 (30.8)	257 (31.1)	255 (30.6)	
<i>Missing values</i>	2	1	1	
<b>Marital status, n (%)</b>				<b>0.017</b>
Living as a couple	616 (37.1)	283 (45.9)	333 (39.9)	
Single, widow, separated/divorced	1044 (62.9)	543 (65.7)	501 (60.1)	
<i>Missing values</i>	2	1	1	
<b>Previous occupation, n (%)</b>				0.790
Farmer, breeder, fisherman	817 (49.3)	409 (49.6)	408 (48.9)	
Others	842 (50.8)	416 (50.4)	426 (51.1)	
<i>Missing values</i>	3	2	1	

Table 2: Factors associated with Toxoplasma seroprevalence (n=1662), EPIDEMCA, 2011-2012

	Not infected n(%)	Infected n(%)	Univariate analysis		Initial multivariate model		Final multivariate model	
			OR (95%CI)	<i>p</i>	OR (95%CI)	<i>p</i>	OR (95%CI)	<i>p</i>
<b>Age (years)</b>				<b>0.029</b>		<b>0.003</b>		<b>0.006</b>
65-69	237 (38.5)	371 (35.4)	1		1		1	
70-74	174 (28.3)	253 (24.2)	0.9 (0.7-1.2)		1.0 (0.7-1.2)		0.9 (0.7-1.2)	
75-79	108 (17.6)	219 (20.9)	<b>1.3 (1.0-1.7)</b>		<b>1.4 (1.1-1.9)</b>		<b>1.4 (1.0-1.8)</b>	
80+	96 (15.6)	204 (19.5)	<b>1.4 (1.0-1.8)</b>		<b>1.5 (1.1-2.1)</b>		<b>1.5 (1.1-2.0)</b>	
<b>Sex</b>				0.111		0.631		
Males	223 (36.3)	421 (40.2)	1		1			
Females	392 (63.7)	626 (59.8)	0.8 (0.7-1.0)		0.9 (0.7-1.2)			
<b>Country</b>				<b>0.002</b>		<b>0.002</b>		<b>0.002</b>
CAR	276 (44.9)	551 (52.6)	1		1		1	
ROC	339 (55.1)	496 (47.4)	<b>0.7 (0.6-0.9)</b>		<b>0.7 (0.6-0.9)</b>		<b>0.7 (0.6-0.9)</b>	
<b>Area</b>				<b>0.001</b>				<b>0.001</b>
Rural	348 (56.6)	467 (44.6)	1		1		1	
Urban	267 (43.4)	580 (55.4)	<b>1.6 (1.3-2.0)</b>		<b>1.4 (1.1-1.8)</b>		<b>1.4 (1.2-1.8)</b>	
<b>Education</b>				<b>0.019</b>		0.288		
No education	446 (72.6)	702 (67.1)	1		1			



At least primary school	168 (27.4)	344 (32.9)	<b>1.3 (1.0-1.6)</b>	1.2 (0.9-1.5)		
<b>Marital status</b>				0.587		
Single, widow, separated/divorced	381 (62.1)	663 (63.4)	1	-		
Living as a couple	233 (38.0)	383 (36.6)	0.9 (0.8-1.2)	-		
<b>Previous occupation</b>				<b>&lt;0.001</b>	<b>0.013</b>	<b>0.002</b>
Others	270 (44.0)	572 (54.7)	1	1	1	
Farmer, breeder, fisherman	344 (56.0)	473 (45.3)	<b>0.6 (0.5-0.8)</b>	<b>0.7 (0.6-0.9)</b>	<b>0.7 (0.6-0.9)</b>	

---

CAR, Central African Republic; CI, Confidence Interval; OR, Odds ratio; ROC, Republic of Congo

Table 3. Characteristics of participants according to dementia diagnosis, EPIDEMCA, 2011-2012

	<b>No dementia (n=1286)</b>	<b>Dementia (n=100)</b>	<b>p</b>
<b>Age (years)</b>			<0.001
65-69	528 (41.1)	13 (13.0)	
70-74	343 (26.7)	16 (16.0)	
75-79	226 (17.6)	20 (20.0)	
80+	189 (14.7)	51 (51.0)	
<b>Females</b>	713 (55.4)	80 (80.0)	<0.001
<b>CAR</b>	627 (48.8)	57 (57.0)	0.112
<b>ROC</b>	659 (51.2)	43 (43.0)	
<b>Rural</b>	592 (46.0)	51 (51.0)	0.337
<b>No education</b>	814 (63.3)	88 (88.9)	<0.001
<i>missing data</i>		0	1
<b>Living as a couple</b>	539 (41.9)	22 (22.2)	<0.001
<i>missing data</i>		0	1
<b>Farmer, breeder, fisherman</b>	575 (44.8)	61 (61.6)	0.001
<i>missing data</i>		0	1
<b>Cognitive score (median, IQR)</b>	28.5 (25.4-30.4)	19.1 (15.3-21.9)	<0.001
<b><i>T.gondii</i> infection (positive)</b>	815 (63.4)	64 (64.0)	0.900
<b>Anti-IgG titers (median, IQR)</b>	32 (0.0-120.0)	40.5 (1.0-11.5)	0.421

CAR: Central African Republic; IQR: interquartile range





Figure 1: Flow chart of study sample, EPIDEMCA, 2011-2012



CAR Central African Republic; ROC Republic of Congo

Figure 2: Seroprevalence of *Toxoplasma* infection based on country and area, EPIDEMCA, 2011-2012.




Figure 3: Prevalence of dementia based on quintiles of anti-*Toxoplasma* IgG titres (n=1,386), EPIDEMCA, 2011-2012.